The BioPharm Brief: Breakthroughs, Buyouts, and Biologics

May 04, 09:07 PM
Headliner
Share
Subscribe

FDA approvals, biotech acquisitions, and clinical trial updates are shaping today’s biopharma landscape. This episode of The BioPharm Brief covers the first approved PROTAC therapy for breast cancer, UCB’s planned acquisition of Candid Therapeutics, and new clinical data from Takeda Pharmaceutical Company in primary immunodeficiency.

Share
Subscribe
Next
The BioPharm Brief: Breakthrough Biologics and Long-Term Wins in IBD and Beyond
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief